Navigation Links
Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
Date:3/29/2011

be deemed to be the beneficial owner of 203 unexpired option contracts each representing 100 shares of Common Stock.

As of the date hereof, Mr. Pearson and Ms. Little do not beneficially own or own of record any interest in the securities of Cephalon.

Investors and security holders may obtain further information regarding Valeant and the names, affiliations and interests of Valeant's directors and executive officers in Valeant's Annual Report on Form 10-K for the year ended December 31, 2010, which was filed with the SEC on February 28, 2011.  These documents can be obtained free of charge from the sources indicated above.  Additional information regarding the interests of the participants in any consent solicitation commenced by Valeant and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the consent solicitation statement and other relevant materials that will be filed with the SEC by Valeant if such a solicitation is commenced (when they become available).

PRIVATE AND CONFIDENTIAL

March 18, 2011

To: The Cephalon, Inc. Board of Directors
Attention: Mr. Kevin Buchi, Chief Executive Officer and Director
41 Moores Road
Frazer, PA 19355

Dear Kevin:

Thank you for making the time on March 3rd to discuss with me ways in which Cephalon and Valeant might work together to create value for both our shareholders.  Since that time, we have continued to review Cephalon in greater detail with our Board of Directors.  We are very enthusiastic about the potential for a combination between our companies and are pleased to submit this non-binding proposal to acquire 100% of the outstanding common shares of Cephalon, Inc. ("Cephalon" or the "Company").  

Our management team has developed a track record over the last three years of successfully acquiring and consolidating
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 2010 MMRSS, which has been,expanding its geographic footprint over the past 5 years, announced the,opening of ... , , ... Thailand , Indonesia , Sri,Lanka , Bangladesh , Vietnam and UAE, has ... , , ...
... , SUNNYVALE, Calif. , Aug. 3 Accuray Incorporated ... field of radiosurgery, announced today it received Shonin approval from the Japanese ... Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive ... as the "CyberKnife® Radiosurgery System." , ...
Cached Medicine Technology:MMRSS now in Hong Kong, Singapore and Taiwan 2Accuray's CyberKnife® G4 System Receives Shonin Approval 2Accuray's CyberKnife® G4 System Receives Shonin Approval 3Accuray's CyberKnife® G4 System Receives Shonin Approval 4
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... research team led by Cesar A. Arias, M.D., Ph.D., ... Houston (UTHealth) has identified a new superbug that caused ... appeared in the April 17 issue of The ... superbug is part of a class of highly-resistant bacteria ... which is a major cause of hospital and community-associated ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... predictive models of human disease is likely following ... (ESF), which urged for a collaborative effort between ... an enormous amount of data from different sources ... of human tissue, and in vitro laboratory experiments. ...
... WASHINGTON, Nov. 12 The Service Employees,International Union (SEIU), ... the following statement in support of the diagnosis of,and ... by,Senator Max Baucus (D-MT) today:, On the heels ... their top overall issues -- and health care costs ...
... as Rainmakers, SAN DIEGO, Nov. 12 New ... of nurses as hospital revenue,generators, according to a new ... staffing company in,the nation, the survey of 305 hospital ... and the emerging role of nurses as,financial rainmakers., ...
... Pharmaceuticals Inc.,announces the promotion of William N. ... Orthopaedics and Urology Business Unit, recently formed ... formerly Executive Director of,Ferring,s Orthopaedics Business Unit., ... In his new role, Garbarini is responsible ...
... components will feature its productivity maximizing products at ASCB Meeting in San ... ... 2008 -- InVitria InVitria announced today that it will showcase ... Biology Meeting on Dec. 13-17 in San Francisco, CA. InVitria provides animal ...
... record lows,the nation,s stress level hits record highs, but despite ... being more stressed,than ever. In his latest book, Life from ... advice such as, "don,t worry, just,stay calm," not only doesn,t ... problem is explained by new information on the nature of ...
Cached Medicine News:Health News:Computers make sense of experiments on human disease 2Health News:Computers make sense of experiments on human disease 3Health News:SEIU Statement in Support of New Blueprint to Solve Health Care Crisis by Senator Max Baucus 2Health News:AMN Survey: Nurses to Have Bigger Impact on Hospital Revenue 2Health News:Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit 2Health News:Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit 3Health News:InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting 2Health News:InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting 3Health News:Stress Spikes as Economy Tanks - Psychologist Identifies Why Traditional 'Stress Management' Techniques Don't Work, and Offers Radical New Approach 2
Pilling-Weck, medium clip size, 10mm, rotatable take apart...
Insert only, Ethicon, small clip size...
Ethicon, medium clip size, 10mm, rotatable take apart...
... The Wako CRP-HS assay utilizes turbidimetric ... procedure, measuring over the range of 0.2-28.0 ... can be adapted to most clinical chemistry ... performance in terms of precision, linearity, correlation, ...
Medicine Products: